Breaking Short Interest: What Will Happen to Chemocentryx Incorporated (NASDAQ:CCXI) Next? The Stock Has Increase in Shorts

November 29, 2016 - By Ruchi Gupta   ·   0 Comments

Breaking Short Interest: What Will Happen to Chemocentryx Incorporated (NASDAQ:CCXI) Next? The Stock Has Increase in Shorts

The stock of Chemocentryx Incorporated (NASDAQ:CCXI) registered an increase of 2.98% in short interest. CCXI’s total short interest was 1.80M shares in November as published by FINRA. Its up 2.98% from 1.75 million shares, reported previously. With 183,400 shares average volume, it will take short sellers 10 days to cover their CCXI’s short positions. The short interest to Chemocentryx Incorporated’s float is 8.96%. The stock decreased 1.35% or $0.11 during the last trading session, hitting $8.03. ChemoCentryx Inc (NASDAQ:CCXI) has risen 225.10% since April 26, 2016 and is uptrending. It has outperformed by 219.84% the S&P500.

ChemoCentryx, Inc. is a biopharmaceutical company. The company has a market cap of $384.35 million. The Firm is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It currently has negative earnings. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Insitutional Activity: The institutional sentiment decreased to 1.03 in Q2 2016. Its down 0.08, from 1.11 in 2016Q1. The ratio worsened, as 12 funds sold all ChemoCentryx Inc shares owned while 23 reduced positions. 20 funds bought stakes while 19 increased positions. They now own 22.71 million shares or 5.49% less from 24.03 million shares in 2016Q1.
The California-based California State Teachers Retirement System has invested 0% in ChemoCentryx Inc (NASDAQ:CCXI). Baker Bros Advsr Lp last reported 49,064 shares in the company. Blackrock Fund Advsr, a California-based fund reported 1.16 million shares. Manufacturers Life Insurance The last reported 1,339 shares in the company. Connective Ltd accumulated 2.58% or 191,881 shares. Geduld E E, a New York-based fund reported 25,000 shares. Bogle Management Lp De holds 0.02% or 75,299 shares in its portfolio. Citadel Lc accumulated 0% or 67,085 shares. Wasatch Inc holds 0.18% of its portfolio in ChemoCentryx Inc (NASDAQ:CCXI) for 2.57M shares. Goldman Sachs Grp Inc accumulated 0% or 56,389 shares. Keybank Natl Association Oh reported 70,766 shares or 0% of all its holdings. Tiaa Cref Investment Mngmt Limited Com last reported 0% of its portfolio in the stock. Paw accumulated 150,000 shares or 0.77% of the stock. Moreover, Oxford Asset has 0.1% invested in ChemoCentryx Inc (NASDAQ:CCXI) for 536,521 shares. The New York-based Bnp Paribas Arbitrage Sa has invested 0% in ChemoCentryx Inc (NASDAQ:CCXI).

Insider Transactions: Since September 1, 2016, the stock had 0 insider buys, and 4 selling transactions for $321,704 net activity. LUCAS ROGER C had sold 4,000 shares worth $24,411. Bekker Petrus also sold $10,375 worth of ChemoCentryx Inc (NASDAQ:CCXI) shares.

CCXI Company Profile

ChemoCentryx, Inc. (ChemoCentryx), incorporated on November 8, 1996, is a biopharmaceutical company. The Firm is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>